Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway

Figure 2

IL-17A induces ERK1/2 MAPK phosphorylation in SSc patient-derived DVSMCs. (A) SSc patient-derived DVSMCs were treated with 100 ng/ml IL-17A for 15, 30, 45 and 60 min, and the phosphorylation of ERK1/2, p38 MAPK and JNK were detected using Western blot. (B) The cells were exposed to the serum of SSc patients or healthy controls for 30 min, the phosphorylation of ERK1/2, p38 MAPK and JNK were detected by Western blot. (C) The cells were incubated with IL-17A (100 ng/ml) in the presence of PD98059 (10 μM/ml) for 30 min, the phosphorylation of ERK1/2 was detected using Western blot. (D) The cells were incubated with 5% SSc serum or healthy serum in the presence of PD98059 (10 μM/ml) for 30 min, the phosphorylation of ERK1/2 was detected using Western blot. GAPDH was used as a loading control. The experiment was repeated three times. DVSMCs, dermal vascular smooth muscle cells; ELISA, enzyme-linked immunosorbent assay; ERK, extracellular-regulated protein kinases; IL-17A, interleukin-17A; JNK, Jun N-terminal kinase; MAPK, mitogen-activated protein kinases; SSc, systemic sclerosis.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us